EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher J Edwards, Kimme L Hyrich, Janet Pope, Savia de Souza, Tanja Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Myrna Cardiel, Katerina Chatzidionysiou, Cătălin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques‐Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde
Annals of the Rheumatic Diseases, 2022
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
- Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 2018
- Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010 2018
- Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs 2022
- Profile of Patients with Rheumatoid Arthritis: a Descriptive Analysis 2022
- Correction to: Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database 2023
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis 1998
- Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study 2012
- Interleukin‐6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute‐phase reactants 2010
- Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis 2013
- Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up 1990